If Managers could vote for a Healthcare growth paradise on earth, it would certainly be for the CIS or CEE Markets! The crisis is gone and the CIS or CEE healthcare markets develop well. No other place on earth does show sales growth numbers of more than 15%.

More and more Russian investors and Pharma companies are interested in West- European healthcare and Pharma / OTC targets. Nowadays the CIS and CEE Pharma markets develop very well, mostly above 15-17%. However the markets are still dominated by more than 80% imported products from West-Europe, Asia and the US. Will this change? What will change?

X5 Retail Group N.V. and “Mosoblformatsiya” announced about signing a joint agreement to establish a network of 60 supermarkets combined with pharmacies in the suburbs of Moscow. The Management believes to sell more units per sqm. compared to traditional pharmacy or supermarket outlets.

The largest Polish pharmaceutical company Polpharma has purchases a controlling share of the largest Kazakh domestic drug manufacturer KhimPharm. The new company will promote its medicine production under its well known "Santo" brand name.

Der Apothekenmarkt in den CIS-Ländern und Osteuropa bietet Pharma-Unternehmen gute Wachstumspotenziale und die Chance auf Zusatzgewinne. Ausschlaggebend für den Erfolg sei die Wahl des richtigen Distributionspartners, erklärt Reiner Christensen, Geschäftsführer von Chameleon Pharma Consulting. Das Beratungshaus bietet die notwendige Expertise und das richtige Netzwerk für die Auswahl eines nachhaltigen Partners.

Berlin 17. Mai 2011 – Im Managementteam von Chameleon Pharma Consulting gibt es einen neuen Kopf: Andreas Masel bringt über 35 weitere Jahre Pharma- und OTC-Kompetenz in der Region CIS und Osteuropa in das Berliner Beratungshaus ein. Damit kann Chameleon Pharma Consulting auf mehr als 50 Jahre Pharma-Erfahrung zurückblicken.